| P2093 | author name string | Steve Chung | |
| P2860 | cites work | Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations | Q27027410 |
| | Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial | Q33661884 |
| | Clinical pharmacology of topiramate: a review | Q33893453 |
| | Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review | Q33903296 |
| | Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed | Q34082054 |
| | Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study. | Q34086531 |
| | Treatment of epilepsy in the multiply handicapped | Q34099234 |
| | Epilepsy Care in Developing Countries: Part II of II | Q34183938 |
| | Comparative efficacy of combination drug therapy in refractory epilepsy | Q34240780 |
| | Road to refractory epilepsy: the Glasgow story | Q34343111 |
| | Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children | Q34467278 |
| | Emerging drugs for epilepsy | Q34688725 |
| | The psychosocial burden of epilepsy | Q34792524 |
| | USL255 extended-release topiramate: dose-proportional pharmacokinetics and tolerability in healthy volunteers | Q34822816 |
| | Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy | Q35774112 |
| | Pharmacokinetic interactions of topiramate | Q35881745 |
| | Extended-release formulations for the treatment of epilepsy | Q36909131 |
| | Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity | Q36999739 |
| | Spotlight on topiramate in epilepsy | Q37056600 |
| | Managing patient adherence and quality of life in epilepsy | Q37125509 |
| | The descriptive epidemiology of epilepsy-a review | Q37228015 |
| | Extended-release formulations of antiepileptic drugs: rationale and comparative value | Q37423598 |
| | Adverse effects of antiepileptic drugs: a brief overview of important issues | Q37762256 |
| | Combining antiepileptic drugs--rational polytherapy? | Q37838580 |
| | Newer drugs for focal epilepsy in adults | Q37979169 |
| | The discovery and development of perampanel for the treatment of epilepsy | Q38190084 |
| | Brivaracetam for the treatment of epilepsy in adults. | Q38195636 |
| | Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action | Q38218764 |
| | Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study | Q40267874 |
| | Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study | Q42862173 |
| | Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age. | Q42873615 |
| | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures | Q42942311 |
| | Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation | Q43642726 |
| | Prevalence, incidence, and classification of epilepsy in the Faroes | Q43995606 |
| | Quantifying the response to antiepileptic drugs: effect of past treatment history | Q44103391 |
| | Low-dose topiramate in adults with treatment-resistant partial-onset seizures | Q44133259 |
| | Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models | Q44907088 |
| | Use of chronic epilepsy models in antiepileptic drug discovery: the effect of topiramate on spontaneous motor seizures in rats with kainate-induced epilepsy | Q45231298 |
| | Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase | Q45269536 |
| | Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine | Q45282325 |
| | Divalproex sodium in children with partial seizures: 12-month safety study. | Q45933912 |
| | Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial | Q46076591 |
| | A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy | Q46606251 |
| | Lamotrigine extended-release as adjunctive therapy for partial seizures | Q46949312 |
| | Pharmacokinetic and pharmacodynamic interactions of aminophylline and topiramate in the mouse maximal electroshock-induced seizure model | Q48262813 |
| | Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study | Q49108158 |
| | Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. | Q51052283 |
| | The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. | Q53926831 |
| P433 | issue | 10 | |
| P304 | page(s) | 1127-1137 | |
| P577 | publication date | 2014-09-13 | |
| P1433 | published in | Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders | Q15760319 |
| P1476 | title | USL255 extended-release topiramate for the treatment of epilepsy | |
| P478 | volume | 14 | |